Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Direct Pulp Capping Agents on Human Pulp Tissue
NCT06435065Phase 4Completed
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, randomised trial of Tristrontium Aluminate in reversible pulpitis (4 arms). Primary endpoints: Radiographic Evaluation of Dentine Bridge Formation via CBCT at 90 days and Histological Evaluation of Pulpal Response and Dentine Bridge Quality at 90 days. Started Apr 2024; status: completed.
02
Drugs
Tristrontium Aluminate
03
Conditions
reversible pulpitis
Beyond the preview
Go deeper on NCT06435065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435065.